A logo is pictured at the World Health Organization (WHO) building in Geneva, Switzerland, February 2, 2020. REUTERS/Denis Balibouse
NAIROBI, Oct 6 (Reuters) – The World Health Organization (WHO) said on Wednesday the only approved vaccine against malaria should be widely given to African children, potentially marking a major advance against a disease that kills hundreds of thousands of people annually.
The WHO recommendation is for RTS,S – or Mosquirix – a vaccine developed by British drugmaker GlaxoSmithKline.
Since 2019, 2.3 million doses of Mosquirix have been administered to infants in Ghana, Kenya and Malawi in a large-scale pilot programme coordinated by the WHO. The majority of those whom the disease kills are under age five.
That programme followed a decade of clinical trials in seven African countries.
“This is a vaccine developed in Africa by African scientists and we’re very proud,” said WHO director-general Tedros Adhanom Ghebreyesus.
“Using this vaccine in addition to existing tools to prevent malaria could save tens of thousands of young lives each year,” he added, referring to anti-malaria measures like bed nets and spraying to kill mosquitoes that transmit the disease.
One of the ingredients in the Mosquirix vaccine is sourced from a rare evergreen native to Chile called a Quillay tree. Reuters reported on Wednesday that the long-term supply of these trees is in question.
Malaria is far more deadly than COVID-19 in Africa. It killed 386,000 Africans in 2019, according to a WHO estimate, compared with 212,000 confirmed COVID-19 deaths in the past 18 months.
The WHO says 94% of malaria cases and deaths occur in Africa, a continent of 1.3 billion people. The preventable disease is caused by parasites transmitted to people by the bites of infected mosquitoes. Symptoms include fever, vomiting and fatigue.
The vaccine’s effectiveness at preventing severe cases of malaria in children is only around 30%, but it is the only approved vaccine. The European Union’s drugs regulator approved it in 2015, saying its benefits outweighed the risks.
“This is how we fight malaria, layering imperfect tools on top of each other,” said Ashley Birkett, who leads global malaria vaccine work at Path, a non-profit global health organization that has funded development of the vaccine with GSK and the three-country pilot.
Another vaccine against malaria called R21/Matrix-Mthat was developed by scientists at Britain’s University of Oxford showed up to 77% efficacy in a year-long study involving 450 children in Burkina Faso, researchers said in April. It is still in the trial stages.
GSK welcomed the WHO recommendation.
“This long-awaited landmark decision can reinvigorate the fight against malaria in the region at a time when progress on malaria control has stalled,” Thomas Breuer, GSK’s chief global health officer, said in a statement.
GSK shares held steady in New York following the announcement, which came after the close of trading in its London-listed shares.
The recommendation was jointly announced in Geneva by the WHO’s top advisory bodies for malaria and immunization, the Malaria Policy Advisory Group and the Strategic Advisory Group of Experts on Immunization.
Experts said the challenge now would be mobilising financing for production and distribution of the vaccine to some of the world’s poorest countries.
GSK has to date committed to produce 15 million doses of Mosquirix annually up to 2028 at a cost of production plus no more than 5% margin.
A global market study led by the WHO this year projected demand for a malaria vaccine would be 50 to 110 million doses per year by 2030 if it is deployed in areas with moderate to high transmission of the disease.
The GAVI vaccine alliance, a global public-private partnership, will consider in December whether and how to finance the vaccination programme.
“As we’ve seen from the COVID vaccine, where there is political will, there is funding available to ensure that vaccines are scaled to the level they are needed,” said Kate O’Brien, director of WHO’s Department of Immunization, Vaccines and Biologicals.
A source familiar with planning for the vaccine’s development said the price per dose was not yet set, but would be confirmed after GAVI’s funding decision and once there is a clear sense of demand.
The WHO’s decision had personal meaning for Dr. Rose Jalong’o, a vaccinology specialist at the Kenyan health ministry.
“I suffered from malaria as a child, and during my internship, and during my clinical years I attended to children in hospital because of severe malaria who needed blood transfusion and unfortunately some of them died,” she said.
“It’s a disease I have grown up with and, seeing all this in my lifetime, it’s an exciting time.”